Ossmiq (Posaconazole)

Posaconazole, the active ingredient in Ossmiq, is an oral triazole antifungal presented as a tablet for systemic use. It treats invasive fungal infections such as aspergillosis and candidiasis in immunocompromised patients. GNH USA supplies Ossmiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Posaconazole is employed across a range of serious fungal infections, targeting the Aspergillus and ​​  ​  ​     ​     ​                                                      ​                       ​ ​    ​    ​  ​  … - Invasive aspergillosis: Reduces fungal burden and improves survival in patients with hematologic malignancy. - Invasive candidiasis: Provides oral step‑down therapy after initial IV treatment. - Prophylaxis of fungal infection: Prevents breakthrough fungal disease in high‑risk neutropenic patients. - Treatment of rare mould infections: Offers activity against Scedan‑  ...

Posaconazole may …  ...

Posaconid...

...